Completion pneumonectomy: A multicentre international study on 165 patients

Giuseppe Cardillo, Domenico Galetta, Paul Van schil, Andrea Zuin, Pierluigi Filosso, Robert J. Cerfolio, Anna Rita Forcione, Francesco Carleo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives: We evaluated factors that influenced morbidity and mortality in patients undergoing completion pneumonectomy (CP). Methods: A retrospective review of a consecutive series of patients who underwent CP at six international centres. Results: In total, 165 CP were performed between March 1990 and December 2009: 152 for malignant disease and 13 for benign disease. Forty-two patients (25.4%) underwent neoadjuvant therapy. Right CP was performed in 99 patients (60%) and left in 66 (40%). Thoracotomy was employed in 161 patients and median sternotomy in 4. Stapled closure of the bronchus was performed in 121 patients and hand closure in 44. The overall operative mortality was 10.3% (17 of 165). Operative mortality was 10.5% (16 of 152) in malignant diseases and 7.7% (1 of 13) in benign diseases. Complications occurred in 55.1% (91 of 165) of patients. Mean hospital stay was 16.02 ± 16.8 days (range: 3-151 days). Thirteen patients (7.9%) developed bronchopleural fistulas. No statistically significant relationship was found in mortality or morbidity according to side, gender, induction therapy and surgical approach. Stapled compared with hand closure for the bronchus did not affect the bronchopleural fistula rate (P = 0.4). The overall 5-year survival was 37.6%: 70.1% in benign disease (13 patients), 48.9% in squamous cell carcinoma of the lung (63 patients), 23.9% in primary lung adenocarcinoma (62 patients), 50% in grade 1 and grade 2 neuroendocrine carcinoma of the lung (4 patients), 54.7% in metastatic disease (14 patients) and 0% in primary lung sarcomas. A statistically significant better survival was observed in patients with squamous cell carcinoma versus adenocarcinoma (P = 0.04). Conclusions: CP shows an acceptable operative mortality with a high morbidity rate. The overall 5-year survival is acceptable in properly selected patients (i.e. squamous cell carcinoma, metastatic disease). Side, gender, induction therapy and surgical approach did not influence mortality and morbidity.

Original languageEnglish
Article numberezs063
Pages (from-to)405-409
Number of pages5
JournalEuropean Journal of Cardio-thoracic Surgery
Volume42
Issue number3
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Pneumonectomy
Multicenter Studies
Mortality
Morbidity
Squamous Cell Carcinoma
Bronchi
Lung
Fistula
Survival
Hand
Neuroendocrine Carcinoma
Neoadjuvant Therapy
Sternotomy
Thoracotomy
Sarcoma

Keywords

  • Completion pneumonectomy
  • Lung cancer
  • Morbidity
  • Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Cardillo, G., Galetta, D., Van schil, P., Zuin, A., Filosso, P., Cerfolio, R. J., ... Carleo, F. (2012). Completion pneumonectomy: A multicentre international study on 165 patients. European Journal of Cardio-thoracic Surgery, 42(3), 405-409. [ezs063]. https://doi.org/10.1093/ejcts/ezs063

Completion pneumonectomy : A multicentre international study on 165 patients. / Cardillo, Giuseppe; Galetta, Domenico; Van schil, Paul; Zuin, Andrea; Filosso, Pierluigi; Cerfolio, Robert J.; Forcione, Anna Rita; Carleo, Francesco.

In: European Journal of Cardio-thoracic Surgery, Vol. 42, No. 3, ezs063, 09.2012, p. 405-409.

Research output: Contribution to journalArticle

Cardillo, G, Galetta, D, Van schil, P, Zuin, A, Filosso, P, Cerfolio, RJ, Forcione, AR & Carleo, F 2012, 'Completion pneumonectomy: A multicentre international study on 165 patients', European Journal of Cardio-thoracic Surgery, vol. 42, no. 3, ezs063, pp. 405-409. https://doi.org/10.1093/ejcts/ezs063
Cardillo, Giuseppe ; Galetta, Domenico ; Van schil, Paul ; Zuin, Andrea ; Filosso, Pierluigi ; Cerfolio, Robert J. ; Forcione, Anna Rita ; Carleo, Francesco. / Completion pneumonectomy : A multicentre international study on 165 patients. In: European Journal of Cardio-thoracic Surgery. 2012 ; Vol. 42, No. 3. pp. 405-409.
@article{4be33782efea42978569da9c65c7ab18,
title = "Completion pneumonectomy: A multicentre international study on 165 patients",
abstract = "Objectives: We evaluated factors that influenced morbidity and mortality in patients undergoing completion pneumonectomy (CP). Methods: A retrospective review of a consecutive series of patients who underwent CP at six international centres. Results: In total, 165 CP were performed between March 1990 and December 2009: 152 for malignant disease and 13 for benign disease. Forty-two patients (25.4{\%}) underwent neoadjuvant therapy. Right CP was performed in 99 patients (60{\%}) and left in 66 (40{\%}). Thoracotomy was employed in 161 patients and median sternotomy in 4. Stapled closure of the bronchus was performed in 121 patients and hand closure in 44. The overall operative mortality was 10.3{\%} (17 of 165). Operative mortality was 10.5{\%} (16 of 152) in malignant diseases and 7.7{\%} (1 of 13) in benign diseases. Complications occurred in 55.1{\%} (91 of 165) of patients. Mean hospital stay was 16.02 ± 16.8 days (range: 3-151 days). Thirteen patients (7.9{\%}) developed bronchopleural fistulas. No statistically significant relationship was found in mortality or morbidity according to side, gender, induction therapy and surgical approach. Stapled compared with hand closure for the bronchus did not affect the bronchopleural fistula rate (P = 0.4). The overall 5-year survival was 37.6{\%}: 70.1{\%} in benign disease (13 patients), 48.9{\%} in squamous cell carcinoma of the lung (63 patients), 23.9{\%} in primary lung adenocarcinoma (62 patients), 50{\%} in grade 1 and grade 2 neuroendocrine carcinoma of the lung (4 patients), 54.7{\%} in metastatic disease (14 patients) and 0{\%} in primary lung sarcomas. A statistically significant better survival was observed in patients with squamous cell carcinoma versus adenocarcinoma (P = 0.04). Conclusions: CP shows an acceptable operative mortality with a high morbidity rate. The overall 5-year survival is acceptable in properly selected patients (i.e. squamous cell carcinoma, metastatic disease). Side, gender, induction therapy and surgical approach did not influence mortality and morbidity.",
keywords = "Completion pneumonectomy, Lung cancer, Morbidity, Mortality",
author = "Giuseppe Cardillo and Domenico Galetta and {Van schil}, Paul and Andrea Zuin and Pierluigi Filosso and Cerfolio, {Robert J.} and Forcione, {Anna Rita} and Francesco Carleo",
year = "2012",
month = "9",
doi = "10.1093/ejcts/ezs063",
language = "English",
volume = "42",
pages = "405--409",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "European Association for Cardio-Thoracic Surgery",
number = "3",

}

TY - JOUR

T1 - Completion pneumonectomy

T2 - A multicentre international study on 165 patients

AU - Cardillo, Giuseppe

AU - Galetta, Domenico

AU - Van schil, Paul

AU - Zuin, Andrea

AU - Filosso, Pierluigi

AU - Cerfolio, Robert J.

AU - Forcione, Anna Rita

AU - Carleo, Francesco

PY - 2012/9

Y1 - 2012/9

N2 - Objectives: We evaluated factors that influenced morbidity and mortality in patients undergoing completion pneumonectomy (CP). Methods: A retrospective review of a consecutive series of patients who underwent CP at six international centres. Results: In total, 165 CP were performed between March 1990 and December 2009: 152 for malignant disease and 13 for benign disease. Forty-two patients (25.4%) underwent neoadjuvant therapy. Right CP was performed in 99 patients (60%) and left in 66 (40%). Thoracotomy was employed in 161 patients and median sternotomy in 4. Stapled closure of the bronchus was performed in 121 patients and hand closure in 44. The overall operative mortality was 10.3% (17 of 165). Operative mortality was 10.5% (16 of 152) in malignant diseases and 7.7% (1 of 13) in benign diseases. Complications occurred in 55.1% (91 of 165) of patients. Mean hospital stay was 16.02 ± 16.8 days (range: 3-151 days). Thirteen patients (7.9%) developed bronchopleural fistulas. No statistically significant relationship was found in mortality or morbidity according to side, gender, induction therapy and surgical approach. Stapled compared with hand closure for the bronchus did not affect the bronchopleural fistula rate (P = 0.4). The overall 5-year survival was 37.6%: 70.1% in benign disease (13 patients), 48.9% in squamous cell carcinoma of the lung (63 patients), 23.9% in primary lung adenocarcinoma (62 patients), 50% in grade 1 and grade 2 neuroendocrine carcinoma of the lung (4 patients), 54.7% in metastatic disease (14 patients) and 0% in primary lung sarcomas. A statistically significant better survival was observed in patients with squamous cell carcinoma versus adenocarcinoma (P = 0.04). Conclusions: CP shows an acceptable operative mortality with a high morbidity rate. The overall 5-year survival is acceptable in properly selected patients (i.e. squamous cell carcinoma, metastatic disease). Side, gender, induction therapy and surgical approach did not influence mortality and morbidity.

AB - Objectives: We evaluated factors that influenced morbidity and mortality in patients undergoing completion pneumonectomy (CP). Methods: A retrospective review of a consecutive series of patients who underwent CP at six international centres. Results: In total, 165 CP were performed between March 1990 and December 2009: 152 for malignant disease and 13 for benign disease. Forty-two patients (25.4%) underwent neoadjuvant therapy. Right CP was performed in 99 patients (60%) and left in 66 (40%). Thoracotomy was employed in 161 patients and median sternotomy in 4. Stapled closure of the bronchus was performed in 121 patients and hand closure in 44. The overall operative mortality was 10.3% (17 of 165). Operative mortality was 10.5% (16 of 152) in malignant diseases and 7.7% (1 of 13) in benign diseases. Complications occurred in 55.1% (91 of 165) of patients. Mean hospital stay was 16.02 ± 16.8 days (range: 3-151 days). Thirteen patients (7.9%) developed bronchopleural fistulas. No statistically significant relationship was found in mortality or morbidity according to side, gender, induction therapy and surgical approach. Stapled compared with hand closure for the bronchus did not affect the bronchopleural fistula rate (P = 0.4). The overall 5-year survival was 37.6%: 70.1% in benign disease (13 patients), 48.9% in squamous cell carcinoma of the lung (63 patients), 23.9% in primary lung adenocarcinoma (62 patients), 50% in grade 1 and grade 2 neuroendocrine carcinoma of the lung (4 patients), 54.7% in metastatic disease (14 patients) and 0% in primary lung sarcomas. A statistically significant better survival was observed in patients with squamous cell carcinoma versus adenocarcinoma (P = 0.04). Conclusions: CP shows an acceptable operative mortality with a high morbidity rate. The overall 5-year survival is acceptable in properly selected patients (i.e. squamous cell carcinoma, metastatic disease). Side, gender, induction therapy and surgical approach did not influence mortality and morbidity.

KW - Completion pneumonectomy

KW - Lung cancer

KW - Morbidity

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=84872674487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872674487&partnerID=8YFLogxK

U2 - 10.1093/ejcts/ezs063

DO - 10.1093/ejcts/ezs063

M3 - Article

C2 - 22398467

AN - SCOPUS:84872674487

VL - 42

SP - 405

EP - 409

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 3

M1 - ezs063

ER -